Largest Valeant Shareholder John Paulson Joins Drugmaker's Board

Jay Anderson
June 19, 2017

193.03 million shares or 13.22% less from 222.43 million shares in 2016Q3 were reported.

Davis Selected Advisers reported 7.00 million shares. Following the transaction, the director now owns 70,572 shares of the company's stock, valued at approximately $980,950.80. $257,280 worth of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares were bought by Herendeen Paul. Comerica Commercial Bank invested in 0% or 20,145 shares.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last released its earnings results on Tuesday, May 9th. France-based Cap Fund Mngmt Sa has invested 0% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Deutsche Bank AG decreased their price target on shares of Valeant Pharmaceuticals International from $20.00 to $19.00 and set a "hold" rating on the stock in a report on Tuesday, March 7th. Winfield Assocs Inc holds 0% or 90 shares in its portfolio. Us Commercial Bank De reported 492 shares. Conning owns 109,769 shares or 0.06% of their United States portfolio. Hap Trading Limited Liability reported 1.29 million shares stake. Ig Invest Management holds 48,900 shares. Cibc Asset Mgmt holds 0.05% or 484,618 shares in its portfolio. The financial firm set Overweight rating on the stock.

Since March 13, 2017, it had 3 insider purchases, and 1 insider sale for $166.26 million activity. Pershing Square Capital Management - L.P. sold 18.11M shares worth $199.26 million. Herendeen Paul bought 24,000 shares worth $257,280.

In other news, Director Schutter Richard U. De bought 20,000 shares of the firm's stock in a transaction dated Thursday, May 11th.

Fantastic Fakhar hits maiden ton as Pakistan post huge target
Amir had been ruled out of Pakistan's semi-final against England due to a back spasm during a practice session. THE 2016 IPL will start on 5 April and run until 21 May, and some stars are going to be raking in the cash.

Research analysts at Cantor Fitzgerald began coverage on shares of Valeant Pharmaceuticals International VRX (NYSE:VRX) in an analyst note made public on 16 June. The third largest holder is Toronto Dominion Bank, which now holds $151.42 million worth of this stock and that ownership represents almost 3.42% of its market capitalization. Three investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Therefore 0 are positive. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has "Neutral" rating given on Thursday, May 11 by BTIG Research. The 50 day moving average was up by +3.25% whereas the 200 day moving average was down $-0.33 or -2.50%. On average, analysts predict that Valeant Pharmaceuticals International, Inc. will post $3.89 EPS for the current year. The firm has "Overweight" rating given on Thursday, November 10 by Morgan Stanley. On December 15 the company was downgraded to "Equal-Weight" from "Neutral" with a current price target of $17.00 in a statement from Morgan Stanley. Canaccord Genuity maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) rating on Wednesday, March 16. The rating was maintained by RBC Capital Markets with "Sector Perform" on Wednesday, November 9. (NYSE VRX) traded down 2.73% during mid-day trading on Thursday, reaching $12.12. Moreover, Alps Advisors Inc has 0% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). The stock has "Buy" rating by Stifel Nicolaus on Wednesday, March 16. As per Wednesday, June 8, the company rating was maintained by Jefferies.

The stock increased 4.50% or $0.55 on June 16, reaching $12.66.

Shares of Valeant Pharmaceuticals International, Inc. It has underperformed by 55.52% the S&P500. Paulson & Co. Inc. owns $245.41 million in Valeant Pharmaceuticals International, Inc., which represents roughly 5.54% of the company's market cap and approximately 10.87% of the institutional ownership. The company has market cap of $5.60 billion. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It now has negative earnings. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by BadHub

Discuss This Article